QuantaMatrix Inc.

KOSDAQ:A317690 Stock Report

Market Cap: ₩48.4b

QuantaMatrix Past Earnings Performance

Past criteria checks 0/6

QuantaMatrix's earnings have been declining at an average annual rate of -4.4%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 30.6% per year.

Key information

-4.41%

Earnings growth rate

0.18%

EPS growth rate

Biotechs Industry Growth11.70%
Revenue growth rate30.63%
Return on equity-55.67%
Net Margin-588.40%
Last Earnings Update31 Mar 2026

Recent past performance updates

No updates

Recent updates

Analysis Article Oct 13

Does QuantaMatrix (KOSDAQ:317690) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Jun 18

QuantaMatrix (KOSDAQ:317690) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article Nov 26

Health Check: How Prudently Does QuantaMatrix (KOSDAQ:317690) Use Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article Jul 19

Is QuantaMatrix (KOSDAQ:317690) Using Debt In A Risky Way?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysis Article Mar 10

What Type Of Shareholders Make Up QuantaMatrix Inc.'s (KOSDAQ:317690) Share Registry?

Every investor in QuantaMatrix Inc. ( KOSDAQ:317690 ) should be aware of the most powerful shareholder groups...

Revenue & Expenses Breakdown

How QuantaMatrix makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A317690 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 263,396-19,98411,4034,310
31 Dec 253,688-19,46011,2184,310
30 Sep 253,350-23,3169,8124,790
30 Jun 253,017-23,3089,6244,790
31 Mar 252,726-19,9869,8444,790
31 Dec 242,497-20,16910,2334,790
30 Sep 243,746-16,64817,3791,247
30 Jun 243,605-17,94316,9622,789
31 Mar 243,483-20,22116,0894,161
31 Dec 233,118-21,55615,5505,778
30 Sep 231,606-20,46913,8756,067
30 Jun 231,460-19,68813,3185,806
31 Mar 231,333-19,53713,4315,608
31 Dec 221,286-19,23712,8375,492
30 Sep 221,098-20,08313,4645,308
30 Jun 22901-19,67213,0335,144
31 Mar 22789-19,05712,2675,077
31 Dec 21550-18,11611,4065,122
30 Sep 21673-16,59410,7884,572
30 Jun 21665-15,96310,0434,556
31 Mar 211,736-15,0739,1834,717
31 Dec 201,689-14,6598,5674,776
30 Sep 201,885-15,5698,8415,488
30 Jun 201,834-17,0238,7385,736
31 Mar 20709-40,7918,4675,638
31 Dec 19811-63,8118,1235,202
31 Dec 1885-16,0096,1114,050
31 Dec 1747-12,4234,2473,459

Quality Earnings: A317690 is currently unprofitable.

Growing Profit Margin: A317690 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A317690 is unprofitable, and losses have increased over the past 5 years at a rate of 4.4% per year.

Accelerating Growth: Unable to compare A317690's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A317690 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.6%).


Return on Equity

High ROE: A317690 has a negative Return on Equity (-55.67%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 01:36
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

QuantaMatrix Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.